Loading…
Viridian Therapeutics, Inc. is projected to rise to $24.15 by 2027, a +22% move from its current price of $19.74. VRDN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $19.19 | $19.76 | $20.34 | +0.09% |
| Jul 14 | $18.98 | $19.78 | $20.61 | +0.18% |
| Jul 15 | $18.82 | $19.79 | $20.82 | +0.27% |
| Jul 16 | $18.69 | $19.81 | $21.00 | +0.36% |
| Jul 17 | $18.58 | $19.83 | $21.17 | +0.45% |
| Jul 18 | $18.48 | $19.85 | $21.32 | +0.55% |
| Jul 19 | $18.39 | $19.87 | $21.46 | +0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.39 | $19.87 | $21.46 | +0.64% |
| Week 2 | $17.93 | $19.99 | $22.30 | +1.28% |
| Week 3 | $17.60 | $20.12 | $23.00 | +1.92% |
| Week 4 | $17.35 | $20.25 | $23.63 | +2.57% |
| Week 5 | $17.15 | $20.38 | $24.21 | +3.22% |
| Week 6 | $16.97 | $20.51 | $24.77 | +3.88% |
| Week 7 | $16.83 | $20.64 | $25.31 | +4.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Viridian Therapeutics, Inc. is a healthcare company that discovers, develops, and commercializes treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
VRDN is currently trading at $19.40. Its market capitalization is $2.14B and its market rank is 1943. The 2026 forecast shows an average price of $19.40 with a range of $13.30 to $27.90 and a neutral sentiment.
A major floor 32.6% below — a decisive break under it would weaken the trend.
The nearest floor, 20.3% below — buyers have tended to step in here.
The nearest ceiling, 3.7% above — a clean break opens room to run.
A major ceiling 54.0% above — clearing it would confirm fresh momentum.
Key VRDN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VRDN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.85 | Sell | $19.73 | Buy |
| MA 10 | $19.22 | Buy | $19.22 | Buy |
| MA 20 | $18.00 | Buy | $18.43 | Buy |
| MA 50 | $17.05 | Buy | $18.12 | Buy |
| MA 100 | $20.02 | Sell | $19.74 | Buy |
| MA 200 | $24.12 | Sell | $21.13 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.92 | Neutral |
| Stoch RSI (14) | 46.08 | Neutral |
| CCI (20) | 94.26 | Neutral |
| Williams %R (14) | -22.88 | Info |
| MACD (12,26,9) | 0.24 | Buy |
| ROC (12) | 14.24 | Buy |
| Bollinger %B (20,2) | 0.81 | Neutral |
| Stochastic %K (14) | 77.12 | Neutral |
| TRIX (15) | 0.55 | Buy |
| Awesome (5,34) | 2.40 | Buy |
| Ultimate (7,14,28) | 65.98 | Neutral |
| Momentum (10) | 2.35 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 20.38 | Sell |
| ADX (14) | 19.81 | Neutral |
| ATR (14) | 0.52 | Info |
The 30-day technical picture is bullish. RSI14 stands at 70, indicating decisive upward momentum. The 50-day simple moving average is $16.46 and the 200-day simple moving average is $24.11, with a defined support at $15.73 and resistance at $19.40.
The 30-day price range runs from a low of $16.13 to a high of $23.34, outlining a constructive near-term trading band for VRDN.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.30 | $19.74 | $28.40 | 0% | Neutral | |
| $19.10 | $24.15 | $32.37 | +22% | Bullish | |
| $22.70 | $29.56 | $41.21 | +50% | Bullish | |
| $27.77 | $37.09 | $53.30 | +88% | Bullish | |
| $27.55 | $37.62 | $55.46 | +91% | Bullish | |
| $28.33 | $39.46 | $59.49 | +100% | Bullish | |
| $29.78 | $42.27 | $65.02 | +114% | Bullish | |
| $29.88 | $43.17 | $67.61 | +119% | Bullish | |
| $36.41 | $53.49 | $85.18 | +171% | Bullish | |
| $41.86 | $62.48 | $101.06 | +217% | Bullish | |
| $48.69 | $78.20 | $134.93 | +296% | Bullish | |
| $100.06 | $182.48 | $345.84 | +824% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $13.30 | $19.74 | $23.74 | +0.00% |
| August 2026 | $17.67 | $20.90 | $25.41 | +5.88% |
| September 2026 | $17.99 | $21.44 | $26.38 | +2.58% |
| October 2026 | $17.73 | $21.26 | $26.42 | -0.82% |
| November 2026 | $18.05 | $21.76 | $27.27 | +2.36% |
| December 2026 | $18.56 | $22.50 | $28.40 | +3.37% |
Click any year to see its month-by-month VRDN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, VRDN is projected to trade between $13.30 and $28.40, averaging $19.74 — a potential gain of 0% from today's $19.74. A consolidation phase looks the most probable path here.
Viridian Therapeutics, Inc.'s 2027 outlook centres on $24.15, within a $19.10 to $32.37 range. That is up +22% on the projected 2026 average. That marks a +22% change versus current levels. Momentum favours further upside here.
By 2028, VRDN could reach as high as $41.21, with a base case around $29.56 and support toward $22.70 — roughly +50% from $19.74. Buyers look set to stay in control over this stretch.
Expect VRDN to range from $27.77 to $53.30 through 2029. The $37.09 average target implies a +88% move from current prices. That is up +25% on the projected 2028 average. Momentum favours further upside here.
The VRDN price prediction for 2030 points to an average of $37.62 (low $27.55, high $55.46) — a potential gain of +91% on today's $19.74. Buyers look set to stay in control over this stretch.
In 2031, VRDN is projected to trade between $28.33 and $59.49, averaging $39.46 — a potential gain of +100% from today's $19.74. That is up +5% on the projected 2030 average. Momentum favours further upside here.
Viridian Therapeutics, Inc.'s 2032 outlook centres on $42.27, within a $29.78 to $65.02 range. That is up +7% on the projected 2031 average. That marks a +114% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, VRDN could reach as high as $67.61, with a base case around $43.17 and support toward $29.88 — roughly +119% from $19.74. Momentum favours further upside here.
Expect VRDN to range from $36.41 to $85.18 through 2034. The $53.49 average target implies a +171% move from current prices. That is up +24% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The VRDN price prediction for 2035 points to an average of $62.48 (low $41.86, high $101.06) — a potential gain of +217% on today's $19.74. Momentum favours further upside here.
In 2040, VRDN is projected to trade between $48.69 and $134.93, averaging $78.20 — a potential gain of +296% from today's $19.74. That is up +25% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Viridian Therapeutics, Inc.'s 2050 outlook centres on $182.48, within a $100.06 to $345.84 range. That is up +133% on the projected 2040 average. That marks a +824% change versus current levels. Momentum favours further upside here.
Investing $1,000 in VRDN today (≈ 50.658561 VRDN) could be worth
$9,244.26
+$8,244.26 (+824%) by 2050 · US Dollar
Based on the average projected VRDN price of $182.48 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VRDNwould be worth at today's price.
$1,000 invested in VRDN on Jul 10, 2025 (≈ 58.377119 VRDN) would be worth
$1,152.36
+$152.36 (+15.2%) today · 1.15× · US Dollar
Based on a VRDN entry price of $17.13 vs. today's $19.74.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.4 | $1,017.53 | +1.8% |
| 1 month ago | $15.77 | $1,251.74 | +25.2% |
| 3 months ago | $14.95 | $1,320.4 | +32.0% |
| 6 months ago | $32.57 | $606.08 | -39.4% |
| 1 year ago | $17.13 | $1,152.36 | +15.2% |
| All time (5.0y) ago | $17.99 | $1,097.28 | +9.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VRDN forecast.
Our base-case forecast reaches $39.00 around 2031.
Implied market cap at $39.00: $4.31B
The multi-year forecast portrays a bullish trajectory for Viridian Therapeutics. The 2027 average price is $23.92 with a 23.3% ROI and bullish sentiment; the 2028 average is $29.76 with a 53.4% ROI; and the 2029 average is $37.01 with a 90.8% ROI. For 2030, the average price is $37.41 with a 92.8% ROI, and 2031 shows an avg of $39.82 with a 105.3% ROI.
The 2032, 2033, 2034, and 2035 forecasts rise to $42.83 (120.8%), $43.82 (125.8%), $54.96 (183.3%), and $63.56 (227.6%) respectively. In the longer horizon, 2040 shows an average of $81.91 with a 322.2% ROI, and 2050 shows an average of $187.23 with an 865.1% ROI and bullish sentiment. These figures are estimates and not guarantees; actual results will depend on factors that can change over time.
Tap a question to reveal the answer.
The 2030 forecast lists an average price of $37.41 with a minimum of $27.59 and a maximum of $54.73, and a ROI of 92.8% with bullish sentiment.
The forecast shows bullish sentiment from 2027 onward, with rising averages and ROI: 2027 avg $23.92 (ROI 23.3%), 2028 avg $29.76 (ROI 53.4%), 2029 avg $37.01 (ROI 90.8%), and continuing higher through 2050 (ROI 865.1%). 2026 is neutral with avg $19.40 and ROI 0%.
Yes. The 2035 max is $101.71, the 2040 max is $139.58, and the 2050 max is $349.58, indicating potential for hitting or exceeding $100 in the forecast horizon, though these are estimates and not guarantees.
The current price is $19.40 and the market capitalization is $2.14B.
The company changed its name to Viridian Therapeutics, Inc. in January 2021.
Viridian Therapeutics, Inc. Community Discussion
0Share your Viridian Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.